(Total Views: 633)
Posted On: 12/12/2023 9:18:01 PM
Post# of 154918
I heard back from Cytodyn investor relations today re: my 2 questions (# of people treated to-date with LL, and Alzheimer's potential vs Pepinemab).
Re: the first question, they replied -
“…to date, leronlimab has been administered to over 1,500 participants in clinical studies…” The exact figure above 1,500 is uncertain due to placebo population(s) in certain studies."
Re: the Alzheimers query -
"...we will review and consider addressing this question/opportunity in a future call/update."
Just FYI.
Re: the first question, they replied -
“…to date, leronlimab has been administered to over 1,500 participants in clinical studies…” The exact figure above 1,500 is uncertain due to placebo population(s) in certain studies."
Re: the Alzheimers query -
"...we will review and consider addressing this question/opportunity in a future call/update."
Just FYI.
(11)
(0)
